Intermittent Fasting Eases Sjögren's Dry Eye via Gut-Immune Axis
Intermittent fasting reshapes gut microbiota and bile acids to reduce autoimmune inflammation in the lacrimal gland, improving dry eye in mice.
Summary
Sjögren's syndrome is an autoimmune disease that attacks moisture-producing glands, causing severe dry eye. Researchers found that intermittent fasting significantly improved tear production and corneal health in Sjögren's mice by reshaping the gut microbiome. Specifically, fasting boosted the beneficial bacterium Akkermansia muciniphila and elevated bile acids — particularly ursodeoxycholic acid. Either of these, given alone, replicated fasting's benefits. The mechanism appears to involve a rebalancing of immune cells in the lacrimal gland, with fewer inflammatory Th17 cells and more protective CD8+ populations. These findings suggest intermittent fasting could serve as a safe, non-pharmacological strategy for managing Sjögren's-related dry eye in humans.
Detailed Summary
Sjögren's syndrome is a chronic autoimmune condition primarily affecting women, characterized by immune-mediated destruction of the lacrimal and salivary glands. Dry eye is one of its most debilitating symptoms, and current treatments are largely symptomatic. This study investigates whether intermittent fasting — an increasingly recognized immunometabolic intervention — could modify the underlying disease process.
Using a mouse model of Sjögren's syndrome, researchers applied an intermittent fasting protocol and observed meaningful improvements in both tear secretion and corneal surface integrity. They then performed comprehensive gut microbiome analysis via 16S rRNA sequencing alongside fecal metabolomics to identify what changed in the gut ecosystem in response to fasting.
Two key players emerged: Akkermansia muciniphila, a bacterium associated with gut barrier health and immune regulation, and bile acids — specifically ursodeoxycholic acid. Critically, oral supplementation with either Akkermansia or ursodeoxycholic acid alone was sufficient to replicate the therapeutic benefits of intermittent fasting, pointing to a clear mechanistic pathway rather than a broad nonspecific effect.
To understand the local immune changes, the team used single-cell and bulk RNA transcriptomics alongside flow cytometry to map the immune microenvironment of the lacrimal gland. They found a striking reduction in pro-inflammatory Th17 cell infiltration and the emergence of anti-inflammatory CD8+ effector populations — a rebalancing of autoimmune activity at the site of tissue damage.
These findings position intermittent fasting as a systems-level intervention capable of influencing autoimmunity through the gut-immune axis. The translational implications are significant: both Akkermansia supplementation and ursodeoxycholic acid (already an approved drug for other indications) are clinically accessible. Human trials are needed to confirm these benefits, and caution is warranted given the study was conducted entirely in mice.
Key Findings
- Intermittent fasting improved tear secretion and corneal integrity in Sjögren's syndrome mice.
- Fasting elevated Akkermansia muciniphila and bile acids, particularly ursodeoxycholic acid, in the gut.
- Oral Akkermansia or ursodeoxycholic acid alone replicated fasting's therapeutic eye benefits.
- Fasting reduced pro-inflammatory Th17 infiltration and increased protective CD8+ cells in lacrimal glands.
- Results suggest gut microbiota remodeling mediates fasting's anti-autoimmune effects on dry eye.
Methodology
The study used a Sjögren's syndrome mouse model with intermittent fasting as the intervention. Gut microbiome changes were characterized via 16S rRNA sequencing and fecal metabolomics. Lacrimal gland immune remodeling was assessed using single-cell and bulk transcriptomics combined with flow cytometry.
Study Limitations
This study was conducted entirely in mice, and direct translation to human Sjögren's syndrome cannot be assumed. The summary is based on the abstract only, limiting full assessment of methodology and statistical rigor. Long-term safety and efficacy of intermittent fasting or Akkermansia supplementation in women with Sjögren's syndrome have not yet been evaluated in clinical trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: